Innate Pharma (Nasdaq: IPHA) to speak on BTIG bladder cancer panel
Rhea-AI Filing Summary
Innate Pharma S.A., a clinical-stage biotechnology company developing immunotherapies for cancer patients, announced that its EVP Chief Medical Officer, Sonia Quaratino, will join the bladder cancer panel Changing Treatment Landscape in Bladder Cancer at the BTIG Virtual Biotechnology Conference 2026.
The panel is scheduled for July 28, 2026 at 10:30 a.m. EDT / 4:30 p.m. CEST. Innate Pharma highlights a pipeline of antibody-based therapies, including IPH4502 for solid tumors, lacutamab for cutaneous T cell lymphomas, and monalizumab for non-small cell lung cancer, developed in collaboration with AstraZeneca.
Positive
- None.
Negative
- None.
Key Figures
Report date: July 23, 2026
Panel date: July 28, 2026
Panel time (EDT): 10:30 a.m. EDT
+1 more
4 metrics
Report date
July 23, 2026
Date of the report of foreign private issuer
Panel date
July 28, 2026
Date of the BTIG Virtual Biotechnology Conference 2026 bladder cancer panel
Panel time (EDT)
10:30 a.m. EDT
Scheduled start time of the panel discussion in Eastern Daylight Time
Panel time (CEST)
4:30 p.m. CEST
Scheduled start time of the panel discussion in Central European Summer Time
Key Terms
clinical-stage biotechnology company, antibody-engineering, Nectin-4 ADC, cutaneous T cell lymphomas, +2 more
6 terms
clinical-stage biotechnology company medical
"Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies"
antibody-engineering technical
"Leveraging its expertise on antibody-engineering and innovative target identification"
Nectin-4 ADC medical
"including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors"
cutaneous T cell lymphomas medical
"lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas"
non-small cell lung cancer (NSCLC) medical
"monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer (NSCLC)"
A common group of lung cancers that arise from the lungs’ cell lining and grow in ways different from the faster-spreading “small cell” form; think of it as several related varieties of the same illness rather than one single disease. It matters to investors because diagnosis rates, new drugs, diagnostic tests, and clinical trial results for these cancers can drive large, sustained revenue opportunities and regulatory decisions that materially affect healthcare and biotech company valuations.
immuno-oncology medical
"to advance innovation in immuno-oncology"
Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Innate Pharma (IPHA) announce regarding the BTIG conference?
Innate Pharma announced that its EVP Chief Medical Officer, Sonia Quaratino, will participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference 2026, focusing on the changing treatment landscape in bladder cancer on July 28, 2026.
When will Innate Pharma (IPHA) participate in the BTIG bladder cancer panel?
Innate Pharma’s CMO will join the bladder cancer panel on July 28, 2026 at 10:30 a.m. EDT / 4:30 p.m. CEST as part of the BTIG Virtual Biotechnology Conference 2026 program.
Who will represent Innate Pharma (IPHA) on the BTIG bladder cancer panel?
Innate Pharma will be represented by Sonia Quaratino, the Company’s EVP Chief Medical Officer. She will take part in a panel discussion on advances and changes in the treatment landscape for bladder cancer.
What type of company is Innate Pharma (IPHA)?
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients, leveraging antibody-engineering and innovative target identification to create differentiated next-generation antibody therapeutics.
What key drug candidates are in Innate Pharma’s (IPHA) pipeline?
Innate Pharma is advancing several assets, including IPH4502, a Nectin-4 ADC in solid tumors, lacutamab, an anti-KIR3DL2 antibody in cutaneous T cell lymphomas, and monalizumab, an anti-NKG2A antibody in non-small cell lung cancer in collaboration with AstraZeneca.
Which major partners collaborate with Innate Pharma (IPHA)?
Innate Pharma reports collaborations with leading biopharmaceutical companies Sanofi and AstraZeneca, as well as academic and research institutions, to support the development of its cancer immunotherapy pipeline and advance innovation in immuno-oncology.